Text Size

Tryptophan Metabolism in Kidney Disease

This study has been completed.
Sponsor:
Information provided by:
Charite University, Berlin, Germany
ClinicalTrials.gov Identifier:
NCT00758537
First received: September 23, 2008
Last updated: July 13, 2009
Last verified: July 2009
History of Changes
  Purpose

Tryptophan metabolism in kidney disease will be investigated in patients with chronic kidney disease stages (ADOQI 3-5). Tryptophan levels and respective catabolites will be assessed under hemodialysis.


Condition
Chronic Kidney Disease

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:

Drug Information available for: Tryptophan
U.S. FDA Resources

Further study details as provided by Charite University, Berlin, Germany:

Primary Outcome Measures:
  • Course of plasma tryptophan level and levels of tryptophan metabolites under standard low-flux hemodialysis. [ Time Frame: does not apply ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: January 2007
Estimated Study Completion Date: October 2008
Groups/Cohorts
Patients with chronic kidney disease stage 3
patients with chronic kidney disease stage 4
patients with chronic kidney disease stage 5 (ESRD)
Controls (no kidney disease)

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

tertiary care academic center, university hospital

Criteria

Inclusion Criteria:

  • Chronic kidney disease (for > 3months) stages (National Kidney foundation/ADOQI): 3-5

Exclusion Criteria:

  • Signs of infection or systemic inflammation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00758537

Locations
Germany
Charite University Medicine Berlin
Berlin, Germany, 13353
Sponsors and Collaborators
Charite University, Berlin, Germany
Investigators
Principal Investigator: Petra Reinke, Md PhD Charite University Medicine
  More Information

No publications provided

Responsible Party: Prof. Dr. Petra Reinke MD, Charite UNiversity Medicine Berlin, Germany
ClinicalTrials.gov Identifier: NCT00758537     History of Changes
Other Study ID Numbers: TRY1STU
Study First Received: September 23, 2008
Last Updated: July 13, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Charite University, Berlin, Germany:
Assessment of tryptophan and tryptophan catabolites and IDO-activity in patients with chronic kidney disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency
Tryptophan
 Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013